Exelixis stock hits all-time high at 59.73 USD

Exelixis shares reached an all-time high of $59.73, up 44.78% over the past year and 36.75% in six months, supported by investor confidence in its oncology pipeline and CABOMETYX franchise. Q2 2026 adjusted EPS of $0.91 beat the $0.84 consensus, but revenue of $628.69 million missed the $633.8 million estimate and led the company to revise its full-year revenue outlook. The FDA extended by three months its review of zanzalintinib for metastatic colorectal cancer after new safety and efficacy data were submitted, while Citizens maintained a $55 target and BMO initiated at Market Perform with a $54 target.

Analysis

EXEL’s near-term setup is less attractive than the headline valuation suggests: the earnings beat does not offset the more important signal of slower top-line conversion and a reset to full-year expectations. With the equity trading above recent published price targets, incremental buyers now need to underwrite both sustained CABOMETYX growth and successful pipeline expansion rather than a simple earnings-revision story. The key second-order issue is franchise concentration: modest changes in CABOMETYX growth, payer dynamics, or competitive sequencing can have an outsized effect on the multiple.

The FDA amendment creates a three-month period in which the stock is exposed to binary regulatory risk without an operating catalyst sufficiently large to absorb a negative decision. In metastatic colorectal cancer, approval alone would not guarantee meaningful value creation; uptake, label breadth, safety differentiation, and reimbursement versus established later-line alternatives will determine whether zanzalintinib is earnings-accretive. A favorable decision can extend the growth narrative over 6-18 months, but a complete response letter or a narrow label would likely force investors to revalue EXEL as a slower-growth single-franchise oncology company.

Contrarian view: the market may be treating the review extension as administrative, while the designation as a major amendment raises the probability that the new data materially changes the FDA’s benefit-risk assessment. Conversely, a clean approval plus stable CABOMETYX guidance would invalidate the bearish setup, particularly if EXEL holds above $60 and management demonstrates that the revenue-guide revision was isolated rather than demand-related. This is an event-risk trade, not a broad biotech read-through.

Key Decisions for Investors

• Do not chase EXEL above $59-$60 before the revised FDA decision date; risk/reward is unfavorable while the stock is priced near highs and consensus targets remain in the mid-$50s.
• For a 1-3 month tactical position, consider short EXEL against a long XBI hedge only on a break below $55; target $49-$50, with a stop above $61. The thesis is multiple compression from regulatory uncertainty and reduced revenue visibility, not a sector call.
• For long-biased exposure, wait for FDA approval and the first evidence of commercial-label breadth before initiating. A post-decision hold above $60 combined with reaffirmed or raised CABOMETYX guidance would be the confirmation trigger.
• Monitor the revised PDUFA date, approval language, and next-quarter CABOMETYX net-product growth. A complete response letter, narrow label, or further guide-down supports the short; clean approval plus accelerating franchise growth falsifies it.